By Dean Seal
Danaher reported higher earnings and revenue in the fourth quarter from gains in its life-sciences and biotechnology units, though it expects the top line to decline in the first quarter.
The manufacturing conglomerate posted a profit of $1.09 billion, or $1.49 a share, compared with $1.08 billion, or $1.45 a share, in the same quarter a year ago.
Stripping out one-time items, adjusted earnings were $2.14. Analysts surveyed by FactSet had been expecting $2.16 a share.
Sales rose 2% to $6.54 billion, above analyst projections for $6.44 billion, according to FactSet.
Revenue was up 6.3% in its biotechnology segment and 5.3% in its life-sciences division, offsetting a decline in the diagnostics business, its largest top line contributor.
Core revenue, which adjusts for foreign currency translation, acquisitions and divested product lines, was up 1%.
For the quarter ahead, Danaher expects core revenue to decline in the low-single-digit percentage range, but rise about 3% for the full year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 29, 2025 06:29 ET (11:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。